Edwards Lifesciences Corp. Hits New 52-Week High at $84.66

Edwards Lifesciences Corp., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 84.66 on October 29, 2025. This achievement marks a notable point in the company's performance, especially considering its one-year performance of -3.96%, contrasting with the S&P 500's gain of 18.33% during the same period.
With a market capitalization of USD 48,455 million, Edwards Lifesciences maintains a price-to-earnings (P/E) ratio of 30.00, reflecting its valuation in the market. The company has a return on equity of 14.74%, indicating its efficiency in generating profits from shareholders' equity. Additionally, the stock's price-to-book ratio stands at 4.59, providing insight into its valuation relative to its assets.

Despite a dividend yield of 0.00% and a debt-to-equity ratio of -0.33, Edwards Lifesciences continues to navigate the competitive landscape of the pharmaceuticals and biotechnology industry, marking this 52-week high as a noteworthy achievement in its ongoing journey.